NASDAQ:HCM

HUTCHMED (HCM) Stock Price, News & Analysis

HUTCHMED logo
$13.95 -0.45 (-3.12%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About HUTCHMED Stock (NASDAQ:HCM)

Advanced

Key Stats

Today's Range
$13.77
▼
$14.04
50-Day Range
$12.82
▼
$15.38
52-Week Range
$9.77
▼
$16.33
Volume
20,120 shs
Average Volume
50,112 shs
Market Capitalization
$2.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.87
Consensus Rating
Moderate Buy

Company Overview

HUTCHMED is a biopharmaceutical company focused on discovering, developing and commercializing medicines, particularly targeted therapies for cancer. Founded in 2000 as Hutchison China MediTech, the company adopted the HUTCHMED name in 2021.

Its oncology medicines include fruquintinib, marketed in China as Elunate and in the United States and other markets as Fruzaqla through a partner; surufatinib, marketed in China as Sulanda; and savolitinib, marketed in China as Orpathys. The company also maintains a pipeline of investigational medicines for cancer and immunological diseases.

Based in Hong Kong, HUTCHMED conducts research and development in China and works with commercial partners to bring its medicines to patients in China and other international markets.

AI Generated. May Contain Errors.

HUTCHMED Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
21st Percentile Overall Score

HCM MarketRank™: 
1.057385759825 of 5 stars

HUTCHMED scored higher than 21% of companies evaluated by MarketBeat, and ranked 813th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HUTCHMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for HUTCHMED is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    HUTCHMED has only been the subject of 3 research reports in the past 90 days.

  • Read more about HUTCHMED's stock forecast and price target.
  • Earnings Growth

    Earnings for HUTCHMED are expected to decrease by -4.35% in the coming year, from $0.23 to $0.22 per share.

  • Price to Book Value per Share Ratio

    HUTCHMED has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.16% of the float of HUTCHMED has been sold short.
  • Short Interest Ratio / Days to Cover

    HUTCHMED has a short interest ratio ("days to cover") of 7.63.
  • Change versus previous month

    Short interest in HUTCHMED has recently increased by 3.91%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    HUTCHMED does not currently pay a dividend.

  • Dividend Growth

    HUTCHMED does not have a long track record of dividend growth.

  • News Sentiment

    HUTCHMED has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for HUTCHMED this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, HUTCHMED insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.60% of the stock of HUTCHMED is held by insiders.

  • Percentage Held by Institutions

    8.82% of the stock of HUTCHMED is held by institutions.

  • Read more about HUTCHMED's insider trading history.
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HCM Stock News Headlines

HUTCHMED (AIM:HCM) Stock Looks Overvalued On Current Earnings
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Headlines

HCM Stock Analysis - Frequently Asked Questions

HUTCHMED's stock was trading at $13.33 on January 1st, 2026. Since then, HCM shares have increased by 4.8% and is now trading at $13.9650.

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) announced its earnings results on Thursday, July, 30th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.15 by $0.10. The company had revenue of $139.14 million for the quarter, compared to analyst estimates of $304.16 million.
Read the conference call transcript
.

HUTCHMED (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Top institutional investors of HUTCHMED include State Street Corp (0.18%), AIA Group Ltd (0.15%), M&G PLC (0.14%) and Goldman Sachs Group Inc. (0.07%).

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), NIO (NIO), Micron Technology (MU), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/30/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HCM
CIK
1648257
Employees
1,796
Year Founded
2000

Price Target and Rating

High Price Target
$17.00
Low Price Target
$13.60
Potential Upside/Downside
+6.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
5.64
Quick Ratio
5.50

Sales & Book Value

Annual Sales
$548.51 million
Price / Sales
4.44
Cash Flow
$2.55 per share
Price / Cash Flow
5.47
Book Value
$7.17 per share
Price / Book
1.95

Miscellaneous

Outstanding Shares
174,470,000
Free Float
168,186,000
Market Cap
$2.43 billion
Optionable
Optionable
Beta
0.30

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:HCM) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners